Literature DB >> 26206856

Rhesus rotavirus VP4 sequence-specific activation of mononuclear cells is associated with cholangiopathy in murine biliary atresia.

Ashley Walther1, Sujit K Mohanty1, Bryan Donnelly1, Abigail Coots1, Celine S Lages2, Inna Lobeck1, Phylicia Dupree1, Jaroslaw Meller3, Monica McNeal4, Karol Sestak5, Greg Tiao6.   

Abstract

Biliary atresia (BA), a neonatal obstructive cholangiopathy, remains the most common indication for pediatric liver transplantation in the United States. In the murine model of BA, Rhesus rotavirus (RRV) VP4 surface protein determines biliary duct tropism. In this study, we investigated how VP4 governs induction of murine BA. Newborn mice were injected with 16 strains of rotavirus and observed for clinical symptoms of BA and mortality. Cholangiograms were performed to confirm bile duct obstruction. Livers and bile ducts were harvested 7 days postinfection for virus titers and histology. Flow cytometry assessed mononuclear cell activation in harvested cell populations from the liver. Cytotoxic NK cell activity was determined by the ability of NK cells to kill noninfected cholangiocytes. Of the 16 strains investigated, the 6 with the highest homology to the RRV VP4 (>87%) were capable of infecting bile ducts in vivo. Although the strain Ro1845 replicated to a titer similar to RRV in vivo, it caused no symptoms or mortality. A Ro1845 reassortant containing the RRV VP4 induced all BA symptoms, with a mortality rate of 89%. Flow cytometry revealed that NK cell activation was significantly increased in the disease-inducing strains and these NK cells demonstrated a significantly higher percentage of cytotoxicity against noninfected cholangiocytes. Rotavirus strains with >87% homology to RRV's VP4 were capable of infecting murine bile ducts in vivo. Development of murine BA was mediated by RRV VP4-specific activation of mononuclear cells, independent of viral titers.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  RRV; VP4; cholangiocytes; natural killer cells; rotavirus

Mesh:

Substances:

Year:  2015        PMID: 26206856      PMCID: PMC4572408          DOI: 10.1152/ajpgi.00079.2015

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  29 in total

1.  Cellular and humoral autoimmunity directed at bile duct epithelia in murine biliary atresia.

Authors:  Cara L Mack; Rebecca M Tucker; Brandy R Lu; Ronald J Sokol; Andrew P Fontenot; Yoshiyuki Ueno; Ronald G Gill
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

2.  Roles of VP4 and NSP1 in determining the distinctive replication capacities of simian rotavirus RRV and bovine rotavirus UK in the mouse biliary tract.

Authors:  Ningguo Feng; Adrish Sen; Marie Wolf; Phuoc Vo; Yasutaka Hoshino; Harry B Greenberg
Journal:  J Virol       Date:  2010-12-29       Impact factor: 5.103

3.  The rhesus rotavirus gene encoding VP4 is a major determinant in the pathogenesis of biliary atresia in newborn mice.

Authors:  Wei Wang; Bryan Donnelly; Alexander Bondoc; Sujit K Mohanty; Monica McNeal; Richard Ward; Karol Sestak; Shan Zheng; Greg Tiao
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

4.  Degeneration of intrahepatic bile duct with lymphocyte infiltration into biliary epithelial cells in biliary atresia.

Authors:  T Ohya; T Fujimoto; H Shimomura; T Miyano
Journal:  J Pediatr Surg       Date:  1995-04       Impact factor: 2.545

5.  Detection of reovirus RNA in hepatobiliary tissues from patients with extrahepatic biliary atresia and choledochal cysts.

Authors:  K L Tyler; R J Sokol; S M Oberhaus; M Le; F M Karrer; M R Narkewicz; R W Tyson; J R Murphy; R Low; W R Brown
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

Review 6.  Screening and outcomes in biliary atresia: summary of a National Institutes of Health workshop.

Authors:  Ronald J Sokol; Ross W Shepherd; Riccardo Superina; Jorge A Bezerra; Patricia Robuck; Jay H Hoofnagle
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

7.  IRF3 inhibition by rotavirus NSP1 is host cell and virus strain dependent but independent of NSP1 proteasomal degradation.

Authors:  Adrish Sen; Ningguo Feng; Khalil Ettayebi; Michele E Hardy; Harry B Greenberg
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

8.  Cholangiocyte expression of alpha2beta1-integrin confers susceptibility to rotavirus-induced experimental biliary atresia.

Authors:  Mubeen Jafri; Bryan Donnelly; Steven Allen; Alex Bondoc; Monica McNeal; Paul D Rennert; Paul H Weinreb; Richard Ward; Greg Tiao
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-04-24       Impact factor: 4.052

9.  Effector role of neonatal hepatic CD8+ lymphocytes in epithelial injury and autoimmunity in experimental biliary atresia.

Authors:  Pranavkumar Shivakumar; Gregg Sabla; Sujit Mohanty; Monica McNeal; Richard Ward; Keith Stringer; Charles Caldwell; Claire Chougnet; Jorge A Bezerra
Journal:  Gastroenterology       Date:  2007-04-20       Impact factor: 22.682

10.  Rotavirus replication in the cholangiocyte mediates the temporal dependence of murine biliary atresia.

Authors:  Sujit K Mohanty; Bryan Donnelly; Alexander Bondoc; Mubeen Jafri; Ashley Walther; Abigail Coots; Monica McNeal; David Witte; Gregory M Tiao
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

View more
  9 in total

1.  A Point Mutation in the Rhesus Rotavirus VP4 Protein Generated through a Rotavirus Reverse Genetics System Attenuates Biliary Atresia in the Murine Model.

Authors:  Sujit K Mohanty; Bryan Donnelly; Phylicia Dupree; Inna Lobeck; Sarah Mowery; Jaroslaw Meller; Monica McNeal; Greg Tiao
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

2.  The SRL peptide of rhesus rotavirus VP4 protein governs cholangiocyte infection and the murine model of biliary atresia.

Authors:  Sujit K Mohanty; Bryan Donnelly; Inna Lobeck; Ashley Walther; Phylicia Dupree; Abigail Coots; Jaroslaw Meller; Monica McNeal; Karol Sestak; Greg Tiao
Journal:  Hepatology       Date:  2017-01-10       Impact factor: 17.425

3.  Rotavirus Reassortant-Induced Murine Model of Liver Fibrosis Parallels Human Biliary Atresia.

Authors:  Sujit K Mohanty; Inna Lobeck; Bryan Donnelly; Phylicia Dupree; Ashley Walther; Sarah Mowery; Abigail Coots; Alexander Bondoc; Rachel M Sheridan; Holly M Poling; Haley Temple; Monica McNeal; Karol Sestak; Ruchi Bansal; Greg Tiao
Journal:  Hepatology       Date:  2020-02-11       Impact factor: 17.425

Review 4.  Innate Immunity and Pathogenesis of Biliary Atresia.

Authors:  Ana Ortiz-Perez; Bryan Donnelly; Haley Temple; Greg Tiao; Ruchi Bansal; Sujit Kumar Mohanty
Journal:  Front Immunol       Date:  2020-02-25       Impact factor: 7.561

5.  Rhesus rotavirus receptor-binding site affects high mobility group box 1 release, altering the pathogenesis of experimental biliary atresia.

Authors:  Sujit K Mohanty; Bryan Donnelly; Haley Temple; Sarah Mowery; Holly M Poling; Jaroslaw Meller; Astha Malik; Monica McNeal; Greg Tiao
Journal:  Hepatol Commun       Date:  2022-07-22

Review 6.  Non-Human Primate Models of Enteric Viral Infections.

Authors:  Karol Sestak
Journal:  Viruses       Date:  2018-10-05       Impact factor: 5.048

7.  High Mobility Group Box 1 Release by Cholangiocytes Governs Biliary Atresia Pathogenesis and Correlates With Increases in Afflicted Infants.

Authors:  Sujit K Mohanty; Bryan Donnelly; Haley Temple; Ana Ortiz-Perez; Sarah Mowery; Inna Lobeck; Phylicia Dupree; Holly M Poling; Monica McNeal; Reena Mourya; Todd Jenkins; Ruchi Bansal; Jorge Bezerra; Greg Tiao
Journal:  Hepatology       Date:  2021-08       Impact factor: 17.425

8.  T-Bet Deficiency Attenuates Bile Duct Injury in Experimental Biliary Atresia.

Authors:  Sujit K Mohanty; Bryan Donnelly; Haley Temple; Alexander Bondoc; Monica McNeal; Greg Tiao
Journal:  Cells       Date:  2021-12-08       Impact factor: 7.666

9.  Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study.

Authors:  Desiree Witte; Amanda Handley; Khuzwayo C Jere; Nada Bogandovic-Sakran; Ashley Mpakiza; Ann Turner; Daniel Pavlic; Karen Boniface; Jonathan Mandolo; Darren Suryawijaya Ong; Rhian Bonnici; Frances Justice; Naor Bar-Zeev; Miren Iturriza-Gomara; Jim Ackland; Celeste M Donato; Daniel Cowley; Graeme Barnes; Nigel A Cunliffe; Julie E Bines
Journal:  Lancet Infect Dis       Date:  2022-01-20       Impact factor: 71.421

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.